Compounds > paclitaxel
Page last updated: 2024-08-23

paclitaxel and Carcinoma, Papillary

paclitaxel has been researched along with Carcinoma, Papillary in 44 studies

Research

Studies (44)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (6.82)18.2507
2000's26 (59.09)29.6817
2010's15 (34.09)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Blontzos, N; Iavazzo, C; Kalinoglou, N; Vafias, E; Vorgias, G1
Al-Batran, SE; Alsina, M; Bang, YJ; Boku, N; Chung, HC; Conti, I; Evesque, L; Hallwachs, R; Hong, J; Lee, KW; Lichinitser, M; Moehler, MH; Park, SH; Ruiz, EY; Ryu, MH; Schenker, M; Taieb, J; Van Cutsem, E; Wyrwicz, L; Xiong, H1
Enomoto, T; Habiro, T; Hatate, K; Hayashi, K; Oshida, S; Sengoku, N; Watanabe, M1
Mahdi, H; Rizzo, A; Rose, PG1
Gao, H; Han, Y; Yuan, L1
Hoskins, PJ; Le, N; Mazgani, M1
Axtell, AE; Bottsford-Miller, J; Drake, RD; Fader, AN; Gehrig, PA; Gibbons, H; Havrilesky, LJ; Huh, WK; Kelley, JL; Moore, KN; Nagel, C; O'Malley, DM; Rose, PG; Secord, AA; Tuller, E; Walsh, CS; Zanotti, KM1
Atkins, MB; Bylow, KA; McDermott, DF; Posadas, EM; Stadler, WM1
Buttin, BM; Chapman-Davis, E; Hardt, JL; Hoekstra, AV; Kim, JJ; Morgan, J1
Altaras, M; Ben-Harim, Z; Bruchim, I; Fishman, A; Shechter-Maor, G1
Abulafia, O; Lee, YC; Salame, G; Wagreich, A1
Alvarez, RD; Buchsbaum, DJ; Della Manna, DL; Frederick, PJ; Grizzle, WE; Kendrick, JE; Lin, HY; LoBuglio, AF; Oliver, PG; Stockard, CR; Straughn, JM; Zhou, T1
Alboni, C; Bernardi, A; Cacciari, N; Capizzi, E; D'Errico Grigioni, A; De Iaco, P; Denkert, C; Dietel, M; Martoni, AA; Massari, F; Quercia, S; Rosati, F; Rosati, M; Sehouli, J; Veltrup, E; Wirtz, RM; Zamagni, C1
Kawaguchi, H; Koga, C; Nakamura, Y; Nishimura, S; Nishiyama, K; Ohno, S; Shigematsu, H; Shiotani, S; Taguchi, K; Tanaka, K1
Bellone, M; Bellone, S; Casagrande, F; Cocco, E; Paik, D; Richter, CE; Rutherford, TJ; Santin, AD; Schwartz, PE; Siegel, EE1
Chen, D; Ding, LJ; Ren, XC; Teng, XD; Xia, AL; Xia, HP; Xu, ST; Xue, DB; Zhang, SJ1
Abaid, LN; Brown, JV; Goldstein, BH; Lopez, KL; Micha, JP; Rettenmaier, MA1
Fujiwara, K; Kimoto, T; Maeda, T; Makino, T; Nishida, Y; Nomura, Y; Sakata, Y; Tada, H; Takeuchi, N; Ueno, S1
Berkowitz, R; Macklin, EA; Matulonis, U; Viswanathan, AN1
Einstein, MH; Frimer, M; Goldberg, GL; Hou, JY; Huang, GS; Kuo, DY; Mehta, K; Mutyala, S; Reimers, LL1
Fukushima, M; Higashiyama, T; Hirokawa, M; Ito, Y; Kihara, M; Kobayashi, K; Miya, A; Miyauchi, A; Takamura, Y1
Li, M; Mao, N; Pan, L; Yin, J1
Baker, TE; Griffin, SJ; Hale, TW; Liu, T; Milla, M; Wang, H1
De Maria, R; Di Gaudio, F; Di Gesù, G; Di Liberto, D; Florena, A; Patti, M; Ricci-Vitiani, L; Stassi, G; Todaro, M; Zerilli, M1
Bekele, BN; Doan, D; El-Naggar, AK; Holsinger, FC; Jasser, SA; Kim, S; Mandal, M; McMurphy, AB; Myers, JN; Schiff, BA; Sherman, SI; Yeung, SC; Yigitbasi, OG; Younes, MN; Zhou, G1
Camatte, S; Castaigne, D; Dubernard, G; Duvillard, P; Lhommé, C; Morice, P; Pautier, P; Rey, A1
Chew, SH; Chua, EJ; Low, J; Low, JS; Sethi, VK; Soh, LT; Tan, HS; Tay, EH; Wong, EH; Yap, SP1
Malkowicz, SB; Rizzo, TA; Vaughn, DJ1
Cibull, M; Cohn, D; DePriest, PD; Dietrich, CS; Gehrig, P; Giesler, J; Higgins, RV; Huh, W; Hunter, J; Kryscio, R; Manahan, K; Merritt, W; Modesitt, SC; Pavlik, EJ; Powell, M; Puls, L; Reedy, MB; Slomovitz, B; Ueland, FR; van Nagell, JR; Wilder, J1
Birk, CL; Brown, JV; Goldstein, BH; Micha, JP; Rettenmaier, MA1
Bamias, A; Bozas, GT; Dimopoulos, MA; Kastritis, E; Markaki, S; Papadimitriou, CA; Rodolakis, A; Vlahos, G1
Collado, MV; García Villanueva, A; Pérez de Oteyza, J; Rojo, R; Ruiz-Tovar, J1
Cretin, J; Delva, R; Freyer, G; Geay, JF; Martin, J; Provencal, J; Pujade-Lauraine, E; Stefani, L; Touzet, S; Trédan, O; Weber, B1
du Bois, A; Greimel, ER; Hedderich, J; Hilpert, F; Krause, G; Loibl, S; Pfisterer, J; Venhoff, L1
Faerber, GJ; Weizer, AZ; Wolf, JS1
Aravantinos, G; Bafaloukos, D; Bozas, G; Dimopoulos, MA; Fountzilas, G; Kalofonos, H; Kosmidis, P; Papadimitriou, CA1
Bauerschlag, DO; Hilpert, F; Jonat, W; Maass, N; Meinhold-Heerlein, I; Mundhenke, C; Roesel, F; Schem, C; Sturner, KH; Weigel, MT1
Adachi, I; Aoyama, H; Horikoshi, N; Narabayashi, M; Taguchi, T; Takashima, S; Watanabe, T1
Almadrones, L; Barakat, R; Curtin, J; Hakes, T; Hoskins, W; Markman, M1
Campani, R; Delnevo, D; Ferrozzi, F; Schiavi, A1
Bilgrami, S; Bona, RD; Edwards, RL; Feingold, JM; Kapur, D; Khan, AM; Rodriguez-Pinero, F; Tutschka, PJ1
Blackburn, A; Buchanan, A; Cunningham, C; Edelman, G; Kirn, D; Maples, P; Nemunaitis, J; Netto, G; Olson, S; Randlev, B; Tong, A1
Acquino-Parsons, C; Hoskins, PJ; Lee, N; Lim, P; Pike, JA; Swenerton, KD; Wong, F1
Fusco, A; Portella, G; Scala, S; Vecchio, G; Vitagliano, D1

Trials

10 trial(s) available for paclitaxel and Carcinoma, Papillary

ArticleYear
Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 10-01, Volume: 29, Issue:10

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary; Carcinoma, Signet Ring Cell; Choice Behavior; Decision Support Techniques; Esophageal Neoplasms; Esophagogastric Junction; Female; Follow-Up Studies; Humans; International Agencies; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Practice Patterns, Physicians'; Prognosis; Stomach Neoplasms; Survival Rate; Young Adult

2018
Phase II trial of carboplatin and paclitaxel in papillary renal cell carcinoma.
    Clinical genitourinary cancer, 2009, Volume: 7, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Survival Rate; Treatment Outcome

2009
Phase II trial of adjuvant pelvic radiation "sandwiched" between combination paclitaxel and carboplatin in women with uterine papillary serous carcinoma.
    Gynecologic oncology, 2012, Volume: 124, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Carcinoma, Papillary; Cystadenocarcinoma, Serous; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Uterine Neoplasms

2012
Adjuvant sequential chemotherapy and radiotherapy in uterine papillary serous carcinoma.
    Gynecologic oncology, 2005, Volume: 97, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Female; Humans; Middle Aged; Paclitaxel; Radiotherapy, Adjuvant; Treatment Outcome; Uterine Neoplasms

2005
Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged >or=70 years with advanced ovarian cancer--a study by the AGO OVAR Germany.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Cisplatin; Cystadenocarcinoma, Serous; Feasibility Studies; Female; Germany; Humans; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; Quality of Life; Retrospective Studies; Survival Rate; Treatment Outcome

2007
Paclitaxel, epirubicin, and carboplatin in advanced or recurrent endometrial carcinoma: a Hellenic Co-operative Oncology Group (HeCOG) study.
    Gynecologic oncology, 2008, Volume: 110, Issue:1

    Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Endometrial Neoplasms; Epirubicin; Female; Greece; Humans; Injections, Intravenous; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Selection; Recurrence

2008
A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer.
    British journal of cancer, 1996, Volume: 73, Issue:2

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Carcinoma, Medullary; Carcinoma, Papillary; Docetaxel; Female; Humans; Infusions, Intravenous; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Taxoids; Toxicity Tests

1996
Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center protocol 9103: paclitaxel in refractory ovarian cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Papillary; Female; Follow-Up Studies; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Analysis

1996
Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity.
    Gene therapy, 2001, Volume: 8, Issue:10

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenoviridae; Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Carcinoma, Papillary; Carcinoma, Squamous Cell; Colonic Neoplasms; Feasibility Studies; Female; Genetic Therapy; Genetic Vectors; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Osteosarcoma; Paclitaxel; Thyroid Neoplasms

2001
Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Oct-15, Volume: 19, Issue:20

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Combined Modality Therapy; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Analysis

2001

Other Studies

34 other study(ies) available for paclitaxel and Carcinoma, Papillary

ArticleYear
Primary peritoneal serous papillary carcinoma: a case series.
    Archives of gynecology and obstetrics, 2019, Volume: 300, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Bevacizumab; CA-125 Antigen; Carboplatin; Carcinoma, Papillary; Cytoreduction Surgical Procedures; Female; Humans; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies

2019
[A patient with thyroid cancer evaluated according to Response Evaluation Criteria in Solid Tumors during treatment for breast cancer recurrence in hepatic and cervical lymph nodes].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:12

    Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma; Carcinoma, Papillary; Diagnosis, Differential; Female; Humans; Liver Neoplasms; Lymphatic Metastasis; Neck; Paclitaxel; Recurrence; Thyroid Cancer, Papillary; Thyroid Neoplasms

2013
Outcome of recurrent uterine papillary serous carcinoma treated with platinum-based chemotherapy.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2015, Volume: 25, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Papillary; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Paclitaxel; Retrospective Studies; Survival Rate; Treatment Outcome; Uterine Neoplasms

2015
Comparisons of the survival time of patients with ovarian cancer adopting post-operative chemotherapy by use of paclitaxel combined with carboplatin or nedaplatin.
    World journal of surgical oncology, 2016, Jun-24, Volume: 14, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Cystadenocarcinoma, Serous; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Postoperative Care; Prognosis; Survival Rate

2016
Reuse of carboplatin and paclitaxel in patients with relapsed endometrial cancer--the British Columbia Cancer Agency experience.
    Gynecologic oncology, 2008, Volume: 111, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Carcinoma, Papillary; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Paclitaxel; Retrospective Studies; Risk Factors

2008
Stage II uterine papillary serous carcinoma: Carboplatin/paclitaxel chemotherapy improves recurrence and survival outcomes.
    Gynecologic oncology, 2009, Volume: 112, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Carcinoma, Papillary; Combined Modality Therapy; Cystadenocarcinoma, Serous; Disease Progression; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Uterine Neoplasms

2009
Synuclein-gamma (SNCG) may be a novel prognostic biomarker in uterine papillary serous carcinoma.
    Gynecologic oncology, 2009, Volume: 114, Issue:2

    Topics: Apoptosis; Biomarkers, Tumor; Carcinoma, Papillary; Cell Growth Processes; Cell Line, Tumor; Cystadenocarcinoma, Serous; Disease-Free Survival; Female; gamma-Synuclein; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Neoplasm Proteins; Paclitaxel; RNA, Small Interfering; Transfection; Uterine Neoplasms

2009
Combined chemotherapy regimen of carboplatin and paclitaxel as adjuvant treatment for papillary serous and clear cell endometrial cancer.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2009, Volume: 19, Issue:4

    Topics: Adenocarcinoma, Clear Cell; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies

2009
Advanced ovarian carcinoma following bilateral uterine artery embolization: a case report.
    The Journal of reproductive medicine, 2009, Volume: 54, Issue:5

    Topics: Carcinoma, Papillary; Cisplatin; Female; Humans; Leiomyoma; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Uterine Artery Embolization; Uterine Neoplasms

2009
Effect of TRA-8 anti-death receptor 5 antibody in combination with chemotherapy in an ex vivo human ovarian cancer model.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2009, Volume: 19, Issue:5

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Carcinoma, Papillary; Combined Modality Therapy; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Drug Synergism; Endometrial Neoplasms; Female; Humans; Immunoenzyme Techniques; In Situ Nick-End Labeling; Inhibitory Concentration 50; Middle Aged; Ovarian Neoplasms; Paclitaxel; Receptors, TNF-Related Apoptosis-Inducing Ligand; Treatment Outcome

2009
Oestrogen receptor 1 mRNA is a prognostic factor in ovarian cancer patients treated with neo-adjuvant chemotherapy: determination by array and kinetic PCR in fresh tissue biopsies.
    Endocrine-related cancer, 2009, Volume: 16, Issue:4

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Papillary; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Estrogen Receptor alpha; Female; Gene Expression Profiling; Humans; Middle Aged; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate

2009
A case of HER-2-positive advanced inflammatory breast cancer with invasive micropapillary component showing a clinically complete response to concurrent trastuzumab and paclitaxel treatment.
    International journal of clinical oncology, 2010, Volume: 15, Issue:6

    Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Papillary; Female; Humans; Inflammatory Breast Neoplasms; Lymphatic Metastasis; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Treatment Outcome

2010
Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro.
    Gynecologic oncology, 2010, Volume: 119, Issue:1

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Papillary; Cell Line, Tumor; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Epothilones; Female; Humans; Paclitaxel; Receptor, ErbB-2; Tubulin; Uterine Neoplasms

2010
[Clinicopathologic study on 61 cases of uterine papillary serous carcinoma with or without adjuvant therapy].
    Zhonghua bing li xue za zhi = Chinese journal of pathology, 2010, Volume: 39, Issue:10

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary; Chemotherapy, Adjuvant; Cisplatin; Cystadenocarcinoma, Serous; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Menopause; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Survival Rate; Uterine Neoplasms

2010
A pilot study evaluating a novel regimen comprised of carboplatin, paclitaxel, and bevacizumab for advanced-stage ovarian carcinoma.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2010, Volume: 20, Issue:7

    Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Papillary; Cystadenocarcinoma, Serous; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects; Survival Rate; Treatment Outcome

2010
[A case of peritoneal serous papillary carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:8

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Carcinoma, Papillary; Combined Modality Therapy; Female; Humans; Paclitaxel; Peritoneal Neoplasms; Serous Membrane; Tomography Scanners, X-Ray Computed

2011
The importance of chemotherapy and radiation in uterine papillary serous carcinoma.
    Gynecologic oncology, 2011, Volume: 123, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Cystadenocarcinoma, Serous; Disease-Free Survival; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Retrospective Studies; Survival Rate; Uterine Neoplasms

2011
Clinical trial of weekly paclitaxel chemotherapy for papillary thyroid carcinoma with squamous cell carcinoma component.
    Endocrine journal, 2012, Volume: 59, Issue:9

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma; Carcinoma, Papillary; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Humans; Induction Chemotherapy; Paclitaxel; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome

2012
Upregulation of phosphorylated cofilin 1 correlates with taxol resistance in human ovarian cancer in vitro and in vivo.
    Oncology reports, 2013, Volume: 29, Issue:1

    Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents, Phytogenic; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Papillary; Carcinoma, Transitional Cell; Cell Proliferation; Cofilin 1; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; In Vitro Techniques; Middle Aged; Neoplasm Grading; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Phosphorylation; Prognosis; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Cells, Cultured; Up-Regulation

2013
Transfer of carboplatin and paclitaxel into breast milk.
    Journal of human lactation : official journal of International Lactation Consultant Association, 2012, Volume: 28, Issue:4

    Topics: Adult; Antineoplastic Agents; Carboplatin; Carcinoma; Carcinoma, Papillary; Chromatography, High Pressure Liquid; Female; Humans; Lactation; Milk, Human; Paclitaxel; Thyroid Cancer, Papillary; Thyroid Neoplasms

2012
Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10.
    Cancer research, 2003, Oct-15, Volume: 63, Issue:20

    Topics: Aged; Antineoplastic Agents; Apoptosis; bcl-X Protein; Carcinoma; Carcinoma, Papillary; Cell Death; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Humans; Interleukin-10; Interleukin-4; Middle Aged; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Thyroid Gland; Thyroid Neoplasms

2003
Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Dec-15, Volume: 10, Issue:24

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Carcinoma, Papillary; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Mice; Mice, Nude; Paclitaxel; Phosphorylation; Quinazolines; Thyroid Neoplasms; Transforming Growth Factor alpha; Tumor Cells, Cultured

2004
Lymph node spread in stage III or IV primary peritoneal serous papillary carcinoma.
    Gynecologic oncology, 2005, Volume: 97, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Carcinoma, Papillary; Combined Modality Therapy; Cystadenocarcinoma, Serous; Female; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Peritoneal Neoplasms; Retrospective Studies

2005
Chemosensitivity of malignant ovarian-type surface epithelial tumor of testis.
    Urology, 2005, Volume: 66, Issue:3

    Topics: Adult; Antineoplastic Agents; Carboplatin; Carcinoma, Papillary; Female; Humans; Male; Ovary; Paclitaxel; Testicular Neoplasms

2005
The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC).
    Gynecologic oncology, 2005, Volume: 99, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Serous; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Rate; Uterine Neoplasms

2005
Abraxane in the treatment of ovarian cancer: the absence of hypersensitivity reactions.
    Gynecologic oncology, 2006, Volume: 100, Issue:2

    Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Agents, Phytogenic; Carcinoma, Papillary; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Drug Hypersensitivity; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel

2006
Adjuvant chemotherapy with paclitaxel and carboplatin in non-endometrioid carcinoma of the uterus.
    European journal of gynaecological oncology, 2005, Volume: 26, Issue:6

    Topics: Adenocarcinoma, Clear Cell; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Chemotherapy, Adjuvant; Combined Modality Therapy; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome

2005
Papillary serous carcinoma of peritoneum: presentation of 2 cases.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2006, Volume: 8, Issue:10

    Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Chemotherapy, Adjuvant; Cisplatin; Female; Follow-Up Studies; Humans; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Postoperative Care; Radiography, Abdominal; Time Factors; Tomography, X-Ray Computed; Topotecan; Treatment Outcome

2006
Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer? Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Cyclophosphamide; Cystadenocarcinoma, Serous; Feasibility Studies; Female; Geriatric Assessment; Humans; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Retreatment; Survival Rate; Treatment Outcome

2007
Progression of disease despite good endoscopic local control of upper tract urothelial carcinoma.
    Urology, 2007, Volume: 70, Issue:3

    Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease Progression; Docetaxel; Electrocoagulation; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Nephrectomy; Paclitaxel; Taxoids; Ureteroscopy

2007
Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects.
    Journal of cancer research and clinical oncology, 2008, Volume: 134, Issue:12

    Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Carboplatin; Carcinoma, Papillary; Cell Proliferation; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Ovarian Neoplasms; Paclitaxel; Piperazines; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; RNA, Messenger; RNA, Neoplasm; Tissue Array Analysis; Tumor Cells, Cultured

2008
[Fat accumulation in the gastric submucosa secondary to chemotherapy. A case report documented by computerized tomography].
    La Radiologia medica, 1997, Volume: 94, Issue:6

    Topics: Adipose Tissue; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary; Cisplatin; Doxorubicin; Epirubicin; Female; Gastric Mucosa; Humans; Ifosfamide; Lipid Metabolism; Middle Aged; Ovarian Neoplasms; Paclitaxel; Tomography, X-Ray Computed

1997
A novel combination of paclitaxel, etoposide, and cyclophosphamide for stem cell mobilization and tumor cytoreduction in ovarian cancer.
    Journal of hematotherapy & stem cell research, 2000, Volume: 9, Issue:2

    Topics: Alopecia; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Blood Transfusion; Carcinoma, Papillary; Cyclophosphamide; Endometrial Neoplasms; Etoposide; Female; Fever; Hematopoietic Stem Cell Mobilization; Humans; Klebsiella Infections; Leukapheresis; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Serous Membrane; Taxoids

2000
ONYX-015, an E1B gene-defective adenovirus, induces cell death in human anaplastic thyroid carcinoma cell lines.
    The Journal of clinical endocrinology and metabolism, 2002, Volume: 87, Issue:6

    Topics: Adenocarcinoma, Follicular; Adenovirus E1B Proteins; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinogenicity Tests; Carcinoma; Carcinoma, Papillary; Cell Death; Defective Viruses; Doxorubicin; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Rats; Thyroid Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured

2002